Pliant Therapeutics Inc
Suletud
1.14 -0.87
Ülevaade
Aktsiahinna muutus
24h
Min
1.12
Max
1.15
Sissetulek | 3.5M -20M |
|---|---|
Aktsiakasum | -0.32 |
Töötajad | 49 |
EBITDA | 6.6M -22M |
Soovitused | Neutraalne |
|---|---|
12 kuu keskmine prognoos | +128.21% upside |
Järgmine tulemuste avaldamine | 5. aug 2026 |
|---|
Turukapital | -6.8M 74M |
|---|---|
Eelmine avamishind | 2.01 |
Eelmine sulgemishind | 1.14 |
Tehniline skoor
By Trading Central
Kindlus
Very Strong Bearish Evidence
Pliant Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Pliant Therapeutics Inc Prognoos
Hinnasiht
By TipRanks
128.21% tõus
12 kuu keskmine prognoos
Keskmine 2.67 USD 128.21%
Kõrge 3 USD
Madal 2 USD
Põhineb 5 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
